Generic Keppra hits UCB sales
pharmafile | March 3, 2010 | News story | Sales and Marketing | 2009 financials, Keppra, UCB
UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the US for epilepsy drug Keppra.
The drug’s sales fell 28% to 913 million euros, largely as a result of a 58% decline in US revenues, depressing the company’s total sales which ended the year at 3.1 billion euros.
Recently launched products helped take the edge off the generic loses, with Crohn’s treatment Cimzia (certolizumab) growing 87% to 75 million euros and epilepsy treatment Vimpat (lacosamide) up 95% to 46 million euros.
Chief executive Roch Doliveux said: “UCB is progressing to become a patient-centric global biopharmaceutical leader as we delivered three new medicines Cimzia, Vimpat and Neupro in five indications to patients living with serious diseases of the central nervous system and immunology. Our financial results are on track and our debt is successfully re-financed.”
Doliveux continued: “Another pillar of UCB’s sustainable growth will be the realisation of the full potential of our core products: Cimzia, which we expect to reach peak sales of at least 1.5 billion Euro, Vimpat with expected peak sales of at least 1.2 billion Euro and Neupro with estimated peak sales of at least 400 million Euro.
“With the recent appointment of Ismail Kola as executive vice president, UCB and president of UCB New Medicines, we have underlined our commitment to a successful breakthrough phase bringing new medicines to the development pipeline and fostering further sustainable growth.”
UCB’s outlook for 2010 sees an increased focus on core assets, re-deployment of its resources and further advancement of R&D with a simplification of its organisation.
Nevertheless the company expects a further decline in Keppra sales and predicts 2010 growth is likely to be flat with revenue of around 3 billion euros.
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
